Literature DB >> 6188898

Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy.

L Dei Cas, R Bolognesi, F Cucchini, A Fappani, S Riva, O Visioli.   

Abstract

We administered 150 mg of ibopamine orally to 10 patients suffering from idiopathic congestive cardiomyopathy. Hemodynamic function was evaluated by right heart catheterization and by measurement of cardiac output with the thermodilution technique. Ibopamine caused no significant change in heart rate or mean arterial pressure. Cardiac index, stroke volume index, and left ventricular work index all increased significantly by about 30%. Mean pulmonary arterial pressure decreased by about 30%, and systemic vascular resistance decreased by about 20%. The effects peaked at about 3 h and lasted 5-7 h. No side effects were noted. These findings with invasive techniques confirm those of others using noninvasive techniques, and suggest that ibopamine may be useful in the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188898     DOI: 10.1097/00005344-198303000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 3.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure.

Authors:  R J Kasmer; R E Cutler; M A Munger; R C Jarvis; D Hricik; A R Nara; P Goldberg; J A Green
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

5.  Lack of effect of ibopamine, a dopamine pro-drug, on renal function in normal subjects.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 6.  Cardiovascular therapies in the 1990s. An overview.

Authors:  R C Becker; J M Gore
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

7.  Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Authors:  P Ghirardi; B Brusoni; M Mangiavacchi; L Bianco; J Col; M Metra; L Dei Cas
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.

Authors:  L Dei Cas; M Metra; S Nodari; S Riva; C Manca; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 9.  Can new inodilators displace digitalis in the therapy of congestive heart failure?

Authors:  T Kumada; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

10.  Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.

Authors:  C Longhini; L Ansani; G F Musacci; S Aggio; E Baracca; T Toselli; P Ghirardi
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.